Coherus Biosciences, Inc. v. Amgen Inc.
1:19-cv-00139
Overview
Parties
Defendant
Amgen Inc. Operating Company
Represented By
3 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Plaintiff
Coherus Biosciences, Inc. Operating Company
Represented By
2 Attorneys ListedFish & Richardson, P.C.
12390 El Camino Real, San Diego, CA 92130
Fish & Richardson, P.C.
222 Delaware Avenue, 17th Floor, P.O. Box 1114
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 6 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 10,155,039 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2012616981 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2013617695 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2013617704 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2014018636 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 9,861,695 B2 | US Continuation / Sibling | View Official Patent → |
Fresenius Kabi USA, LLC et al. v. Coherus BioSciences, Inc.
Patents Involved
There are 4 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US10155039
Stable aqueous formulations of adalimumab
|
Filed: 2017-10-31
Issued: 2018-12-18
|
Active (10.9 yrs remaining)
Expires: 2037-10-31
|
|
|
US10159732
Stable aqueous formulations of adalimumab
|
Filed: 2017-10-05
Issued: 2018-12-25
|
Active (10.9 yrs remaining)
Expires: 2037-10-05
|
|
|
US10159733
Stable aqueous formulations of adalimumab
|
Filed: 2017-10-05
Issued: 2018-12-25
|
Active (10.9 yrs remaining)
Expires: 2037-10-05
|
|
|
US10207000
Stable aqueous formulations of adalimumab
|
Filed: 2017-10-05
Issued: 2019-02-19
|
Active (10.9 yrs remaining)
Expires: 2037-10-05
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.
Standard Statutory Term β No obviousness-type double patenting truncation noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).
Procedural Motions & Interlocutory Orders
Total Motions
26
Dispositive
0
Granted
0
Denied
0
Pending / Review
13
Motions by Category
Key Dispositive Motions & Rulings